Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine.

Br J Dermatol. 1997 Oct;137(4):577-80. Unique Identifier : AIDSLINE MED/98052036
Herranz P; Garcia J; De Lucas R; Gonzalez J; Pena JM; Diaz R; Casado M; Department of Dermatology, La Paz University Hospital, Autonoma; University, Madrid, Spain.

Abstract: Skin infections caused by dermatophytes are one of the most frequent dermatological complications in patients with acquired immunodeficiency syndrome (AIDS) resulting from infection with human immunodeficiency virus (HIV). Tinea unguium associated with AIDS is characterized by being clinically more aggressive and therapeutically more difficult to treat than in the general population. Terbinafine is considered to be a first-choice option for the treatment of dermatophyte onychomycosis in immunocompetent individuals. This drug has been used in a series of 21 HIV-positive patients diagnosed with tinea unguium for 1 year in the University Hospital La Paz, Madrid. All patients underwent a subsequent clinical follow-up for 6 months. The results showed a high percentage of clinical and mycological cures, as well as maintenance of the response after follow-up; no drug interactions or significant adverse effects related to the drug under study were recorded.
Keywords: Adult Antifungal Agents/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/*DRUG THERAPY/PATHOLOGY Female Follow-Up Studies Foot Dermatoses/DRUG THERAPY/PATHOLOGY Human Male Middle Age Naphthalenes/*THERAPEUTIC USE Onychomycosis/*DRUG THERAPY/PATHOLOGY Treatment Outcome CLINICAL TRIAL JOURNAL ARTICLEKWDadultantifungalagents/KWDtherapeuticuseaids-relatedopportunisticinfections/KWDdrugtherapy/pathologyfemalefollow-upstudiesfootdermatoses/drugtherapy/pathologyhumanmalemiddleagenaphthalenes/KWDtherapeuticuseonychomycosis/KWDdrugtherapy/pathologytreatmentoutcomeclinicaltrialjournalarticle
980228
M9820713

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .